Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer. Padron, L. J., Maurer, D. M., O'Hara, M. H., O'Reilly, E., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G. A., Rahma, O. E., Lyman, J. P., Cabanski, C. R., Yu, J., Pfeiffer, S. M., Spasic, M., Hollmann, T. J., Chen, R., O'Donnell-Tormey, J., Bucktrout, S., LaVallee, T., Vonderheide, R. H. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301178